Google this and study.
oxb agm 2013
Sentiment: Strong Buy
Very nice Sci!
The ophthalmology opportunity:
Conjunctivitis/allergy Market $4.7bn
OXB Portfolio = FILL IN THE BLANK
Noticed that Sanofi removed the other 4-5 out-licensing opportunities that they had listed on their website as well, but this looks very promising for FOV1101!
I look forward to August 1st. Sanofi could easily have wiped FOV1101 off their pipe. They have plans. This candidate has been held to the scrutiny of Fovea and Sanofi among others. Its a good solid go to kind of product.